NanoHybrids harnesses the power of nanotechnology and molecular targeting.
As nanotechnology rapidly expands into the realms of medicine, there is an unmet need for “smart” nanoparticles capable of homing in on diseased tissue while leaving healthy cells intact. When targeted to specific biomarkers, these nanoparticles can provide critical information about the biology of the disease in the context of the anatomy both in vitro and in vivo.Their nano-sized contrast agents can enhance biomedical imaging techniques by interacting specifically with diseased cells and allowing for real time imaging of functional biology. Their products can potentially be employed in a wide variety of applications including optical biomedical imaging, microscopy, molecular diagnostics and theranostic approaches.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 21, 2015 | Grant | $149.99K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |